Latest Lymphocytic Leukemia Stories
Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014
RnRMarketResearch.com adds “EpiCast Report Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023” to its store.
First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/
First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography;
DUBLIN, April 23, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3mgfnj/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic
FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for
- A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
- (in plural) Money; cash.